US 11,965,038 B2
Pharmaceutical composition comprising antibody binding specifically to lysyl-tRNA synthetase N-terminus as effective ingredient for preventing or treating immune cell migration-related disease
Nam Hoon Kwon, Gyeonggi-do (KR); Jin Young Lee, Gyeonggi-do (KR); and Sunghoon Kim, Gyeonggi-Do (KR)
Assigned to Zymedi Co., Ltd., Incheon (KR)
Appl. No. 16/646,240
Filed by Zymedi Co., Ltd., Incheon (KR)
PCT Filed Sep. 17, 2018, PCT No. PCT/KR2018/010903
§ 371(c)(1), (2) Date May 15, 2020,
PCT Pub. No. WO2019/054819, PCT Pub. Date Mar. 21, 2019.
Claims priority of application No. 10-2017-0118917 (KR), filed on Sep. 15, 2017.
Prior Publication US 2021/0070880 A1, Mar. 11, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/40 (2006.01)
CPC C07K 16/40 (2013.01) [C07K 2317/565 (2013.01); C07K 2317/622 (2013.01)] 12 Claims
 
1. A method for treating an immune cell migration-related disease in a subject, the method comprising administering to the subject in need thereof an effective amount of a composition comprising an antibody binding specifically to an epitope containing the sequence of SEQ ID NO: 117 in the N-terminus of lysyl-tRNA synthetase (KRS) or an antigen binding fragment thereof as an effective ingredient,
wherein the antibody or antigen binding fragment thereof comprises:
(a) a heavy chain variable region comprising: a heavy chain complementarity determining region 1 containing the amino acid sequence defined by SEQ ID NO: 1, a heavy chain complementarity determining region 2 containing the amino acid sequence defined by SEQ ID NO: 3 or SEQ ID NO: 151, and a heavy chain complementarity determining region 3 containing the amino acid sequence defined by SEQ ID NO: 5; and a light chain variable region comprising: a light chain complementarity determining region 1 containing the amino acid sequence defined by SEQ ID NO: 7, a light chain complementarity determining region 2 containing the amino acid sequence defined by SEQ ID NO: 9, and a light chain complementarity determining region 3 containing the amino acid sequence defined by SEQ ID NO: 11, SEQ ID NO: 13 or SEQ ID NO: 15;
(b) a heavy chain variable region comprising: a heavy chain complementarity determining region 1 containing the amino acid sequence defined by SEQ ID NO: 1, a heavy chain complementarity determining region 2 containing the amino acid sequence defined by SEQ ID NO: 17, SEQ ID NO: 19, SEQ ID NO: 21 or SEQ ID NO: 23, and a heavy chain complementarity determining region 3 containing the amino acid sequence defined by SEQ ID NO: 5; and a light chain variable region comprising: a light chain complementarity determining region 1 containing the amino acid sequence defined by SEQ ID NO: 7, a light chain complementarity determining region 2 containing the amino acid sequence defined by SEQ ID NO: 9, and a light chain complementarity determining region 3 containing the amino acid sequence defined by SEQ ID NO: 15: or
(c) a heavy chain variable region comprising: a heavy chain complementarity determining region 1 containing the amino acid sequence defined by SEQ ID NO: 1, a heavy chain complementarity determining region 2 containing the amino acid sequence defined by SEQ ID NO: 21, and a heavy chain complementarity determining region 3 containing the amino acid sequence defined by SEQ ID NO: 5 or SEQ ID NO: 25; and a light chain variable region comprising: a light chain complementarity determining region 1 containing the amino acid sequence defined by SEQ ID NO: 7, a light chain complementarity determining region 2 containing the amino acid sequence defined by SEQ ID NO: 9, SEQ ID NO: 27, or SEQ ID NO: 29, and a light chain complementarity determining region 3 containing the amino acid sequence defined by SEQ ID NO: 15,
wherein the immune cell migration-related disease is a cardiovascular disease, a fibrotic disease, an inflammatory disease, or Alport syndrome.